CytRx Names Industry Veteran as President and COO

CytRx Corporation (NASDAQ: CYTR), announced on 5/3/18 that its Board of Directors has approved the appointment of Eric L. Curtis, MBA, to the Company's executive management team, as President and Chief Operating Officer, effective today.

Mr. Curtis brings 25 years of life science leadership experience to CytRx, with a proven track record in oncology and orphan diseases, including the development and commercialization of several approved and marketed cancer drugs such as Votrient®, Doxil®, Velcade®, Benlysta® and Tykerb®.  Most recently, he has provided strategic consultancy services to a variety of healthcare-focused companies, including CytRx. He had previously served as strategic advisor to executive management for the Company's internal development efforts and external partner relationships.

"Over the past few months I have witnessed the transformative capability of CytRx's LADRTM technology to redesign current cancer treatment paradigms," said Mr. Curtis. "As President and Chief Operating Officer, I will dedicate my attention to the partnering of the LADR™ technology and assets, advancing the Company's current programs and future drug candidate discoveries for the benefit of all of our shareholders.  I intend to utilize my significant professional experience and relationships to maximize the success of our scientific programs and execute on CytRx's mission of bringing new treatment options to patients battling cancer."

Mr Curtis' previous experience includes:
President, U.S. Commercial at Aegerion Pharmaceuticals
Vice President and General Manager – Rare Disease/Cardiopulmonary Business Unit at Bayer Healthcare
Vice President, Marketing and Global Commercial Leader, Rare Disease Business Unit – GSK
Mr. Curtis also brings substantial sales and marketing acumen gained through his involvement in several oncology treatments, including Doxil®, Velcade®, and Tykerb®